Eli Lilly beats third-quarter forecasts, raises 2026 revenue outlook to $91 billion-$92 billion

Barron's reports Eli Lilly beat Wall Street's third-quarter forecasts. The Wall Street Journal puts revenue at $24.4 billion, up 39%, on growing demand for Mounjaro and Zepbound. MarketWatch says Lilly now expects $91 billion to $92 billion in 2026 revenue, its third outlook increase this year. Separately, a Journal post puts quarterly profit at $6.45 billion, up from $5.58 billion a year earlier.